Novel treatments for chronic pain


Chronic pain affects 1.5 billion people globally. The economic cost in the US is more than heart disease, cancer, and diabetes combined.

We’re developing therapeutics for chronic pain with less tolerance, dependence and withdrawal.

Programs in development

A portfolio of non-addictive mechanisms for chronic pain, advancing from discovery toward the clinic.

GR-101
Novel analgesic
Chronic rare disease pain
Discovery Preclinical IND-Enabling Phase 1
GR-201
Novel therapeutic
Dependence & tolerance minimization
Discovery Preclinical IND-Enabling Phase 1
GR-301
Novel analgesic
Discovery Preclinical IND-Enabling Phase 1
GR-401
Novel analgesic
Discovery Preclinical IND-Enabling Phase 1

Leadership

David Pearce
Michael Johnson
Kristian Rönn

Open roles

We're a small team building the science to end chronic pain. If that's your life's work too, we want to meet you.

Chemistry San Francisco / Bay Area

Computational Chemist

Drive drug discovery through molecular dynamics and small molecule design, applying computational chemistry to advance our pipeline.

Apply
Legal San Francisco / Bay Area

Patent Strategist

Lead IP strategy by drafting and submitting patents, and build AI agents that accelerate our patent workflow.

Apply

Aligned with our mission? Let's talk.